GENESIS Pharma, a regional biopharma company focused on the commercialization of innovative medicines in Central and Eastern Europe, announces an exclusive agreement with Krystal Biotech, Inc. (NASDAQ: KRYS), a fully-integrated, global biotechnology company specializing in genetic medicines, for the distribution and commercialization of beremagene geperpavec-svdt, a redosable genetic medicine and the first corrective therapy for the treatment of dystrophic epidermolysis bullosa (DEB), in twelve markets in Central and Eastern Europe. Under the terms of the agreement and upon local market approval, GENESIS Pharma will exclusively distribute and commercialize beremagene geperpavec-svdt in Greece, Cyprus, Romania, Bulgaria, Croatia, Malta, Serbia, North Macedonia, Bosnia & Herzegovina, Montenegro, Albania, and Kosovo, addressing the high unmet medical needs of DEB patients.
Beremagene geperpavec-svdt is a non-invasive, topical, redosable genetic medicine indicated for the treatment of wounds in patients with DEB who have mutations in the collagen type VII alpha 1 chain (COL7A1) gene, starting from birth. It is the first corrective medicine approved for the treatment of DEB in Europe, receiving European Commission marketing authorization in April 2025.
Mr. Constantinos Evripides, Managing Director of GENESIS Pharma stated: “We are delighted to initiate our agreement with Krystal Biotech, a company committed to addressing significant unmet medical needs through pioneering genetic medicines. Adding this groundbreaking therapy to our robust portfolio of orphan treatments further strengthens our own commitment to supporting patients with rare and ultra-rare diseases. Together, we will work with dedication and precision to ensure that all eligible patients across our region have timely and seamless access to this innovative therapy.”
About Dystrophic Epidermolysis Bullosa (DEB)
DEB is a rare and severe disease that affects the skin and mucosal tissues. It is caused by one or more mutations in a gene called COL7A1, which is responsible for the production of the protein type VII collagen (COL7) that forms anchoring fibrils that bind the dermis (inner layer of the skin) to the epidermis (outer layer of the skin). The lack of functional anchoring fibrils in DEB patients leads to extremely fragile skin that blisters and tears from minor friction or trauma. DEB patients suffer from open wounds, which lead to skin infections, fibrosis that can cause fusion of fingers and toes, and ultimately an increased risk of developing an aggressive form of squamous cell carcinoma which, in severe cases, can be fatal.
About GENESIS Pharma
GENESIS Pharma is a regional biopharma company focused on the commercialization of innovative biopharmaceutical products targeting severe and rare diseases in Central and Eastern Europe. Established in 1997, GENESIS Pharma was among the first pharmaceutical companies in Europe to specialize in the marketing, sales and distribution of biopharmaceutical products. GENESIS Pharma maintains a strong portfolio in therapeutic areas with high unmet medical need through long standing strategic alliances with some of the leading global biopharma companies. For more information, please visit www.genesispharma.com and follow us on LinkedIn.
For more information, please contact:
Natalia Karahaliou, Communications Manager
nkarahaliou@genesispharma.com
+30 210 87 71 605
Beremagene geperpavec-svdt is a non-invasive, topical, redosable genetic medicine indicated for the treatment of wounds in patients with DEB who have mutations in the collagen type VII alpha 1 chain (COL7A1) gene, starting from birth. It is the first corrective medicine approved for the treatment of DEB in Europe, receiving European Commission marketing authorization in April 2025.
Mr. Constantinos Evripides, Managing Director of GENESIS Pharma stated: “We are delighted to initiate our agreement with Krystal Biotech, a company committed to addressing significant unmet medical needs through pioneering genetic medicines. Adding this groundbreaking therapy to our robust portfolio of orphan treatments further strengthens our own commitment to supporting patients with rare and ultra-rare diseases. Together, we will work with dedication and precision to ensure that all eligible patients across our region have timely and seamless access to this innovative therapy.”
About Dystrophic Epidermolysis Bullosa (DEB)
DEB is a rare and severe disease that affects the skin and mucosal tissues. It is caused by one or more mutations in a gene called COL7A1, which is responsible for the production of the protein type VII collagen (COL7) that forms anchoring fibrils that bind the dermis (inner layer of the skin) to the epidermis (outer layer of the skin). The lack of functional anchoring fibrils in DEB patients leads to extremely fragile skin that blisters and tears from minor friction or trauma. DEB patients suffer from open wounds, which lead to skin infections, fibrosis that can cause fusion of fingers and toes, and ultimately an increased risk of developing an aggressive form of squamous cell carcinoma which, in severe cases, can be fatal.
About GENESIS Pharma
GENESIS Pharma is a regional biopharma company focused on the commercialization of innovative biopharmaceutical products targeting severe and rare diseases in Central and Eastern Europe. Established in 1997, GENESIS Pharma was among the first pharmaceutical companies in Europe to specialize in the marketing, sales and distribution of biopharmaceutical products. GENESIS Pharma maintains a strong portfolio in therapeutic areas with high unmet medical need through long standing strategic alliances with some of the leading global biopharma companies. For more information, please visit www.genesispharma.com and follow us on LinkedIn.
For more information, please contact:
Natalia Karahaliou, Communications Manager
nkarahaliou@genesispharma.com
+30 210 87 71 605